Titmuss, E.; Yu, I.S.; Pleasance, E.D.; Williamson, L.M.; Mungall, K.; Mungall, A.J.; Renouf, D.J.; Moore, R.; Jones, S.J.M.; Marra, M.A.;
et al. Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Curr. Oncol. 2024, 31, 1865-1875.
https://doi.org/10.3390/curroncol31040140
AMA Style
Titmuss E, Yu IS, Pleasance ED, Williamson LM, Mungall K, Mungall AJ, Renouf DJ, Moore R, Jones SJM, Marra MA,
et al. Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Oncology. 2024; 31(4):1865-1875.
https://doi.org/10.3390/curroncol31040140
Chicago/Turabian Style
Titmuss, Emma, Irene S. Yu, Erin D. Pleasance, Laura M. Williamson, Karen Mungall, Andrew J. Mungall, Daniel J. Renouf, Richard Moore, Steven J. M. Jones, Marco A. Marra,
and et al. 2024. "Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors" Current Oncology 31, no. 4: 1865-1875.
https://doi.org/10.3390/curroncol31040140
APA Style
Titmuss, E., Yu, I. S., Pleasance, E. D., Williamson, L. M., Mungall, K., Mungall, A. J., Renouf, D. J., Moore, R., Jones, S. J. M., Marra, M. A., Laskin, J. J., & Savage, K. J.
(2024). Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Oncology, 31(4), 1865-1875.
https://doi.org/10.3390/curroncol31040140